1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc.

PHBI
Pharmagreen Biotech Inc.US flagOther OTC
0.00
USD
- -
- -
622,211.00Market Cap
Pharmagreen Biotech Inc.
PHBI
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.26
-0.04
-0.01
-0.03
-0.02
- -
- -
Basic EPS, GAAP
-0.02
-0.23
-0.04
-0.01
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.04
-0.07
-0.16
-0.06
-0.09
-0.04
-0.03
-0.03
Book Value per Share
0.3
-0.04
-0.06
-0.01
-0.04
-0.01
- -
- -
Tangible Book Value per Share
- -
- -
25
74
82
294
404
449
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-35,807.05
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-1
-1
-2
-5
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-32,093.4
Profit Margin (%)
- -
- -
-2
-1
-3
-2
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
-1
-1
-3
-2
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'23
Jun'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
455
455
464
Market Capitalization
1
2
1

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'23
Jun'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2,460.07%
7.68%
Free Cash Flow
- -
321.1%
106.99%
Net Income, GAAP
- -
327%
-80.68%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
-0.01
- -
- -
-0.02
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Hester Biosciences Limited (HESTERBIO.NS)
Australis Capital Inc. (AUSAF)
Albert David Ltd. (ALBERTDAVD.BO)
Acreage Holdings, Inc. (ACRDF)
LiveWire Ergogenics, Inc. (LVVV)
Jeil Pharma Holdings Inc (002620.KS)
Business
Pharmagreen Biotech Inc. (PHBI) operates as a biotechnology company focused on nutraceutical formulations and advanced plant tissue culture technologies in North America. The company develops and markets MaxGenomic supplement, a proprietary nutrigenomic blend of medicinal mushrooms and therapeutic plants including beta-glucans and lipopolysaccharides to support DNA repair, cellular health, mind, and body function; provides Chibafreen tissue culture services for disease-free starter plantlets using micro-propagation techniques; offers DNA testing for plant genetics verification; delivers live plant storage solutions; supplies consulting on plant genetic selection, standard operating procedures for cultivation, and preservation; and plans IoT greenhouses for cannabis nursery production along with live rosin cannabis concentrates. Headquartered in Coquitlam, British Columbia, Canada, with operations centered in Nevada, the company was incorporated in 2007. Recent developments include a January 2024 supply agreement with SierraSil Health Inc. for trademarked mineral complexes in nutraceutical formulations; October 2024 announcement of significant revenue potential from a major project estimated at up to $32 million by year three; September 2024 reaffirmation of non-toxic financing commitment amid progress on a foreign government collaboration; and ongoing business advancements in nutraceuticals beyond cannabis.

Company News

APIChatGPT

  • globenewswire.com

    Pharmagreen Biotech Inc. (PHBI) Announces Exciting Revenue Potential for Its Project

  • globenewswire.com

    Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Financing Amid Ongoing Business Development Progress

  • accesswire.com

    PHBI - Pharmagreen Signs Supply Contract and Trade Marked Name Use of SierraSil(R) in Its' Nutraceutical Formulations

  • newsfilecorp.com

    Pharmagreen Provides Update on Funding and Acquisition Progress

  • newsfilecorp.com

    Pharmagreen Signs MOU to Acquire a California Based Cannabis Company

  • globenewswire.com

    Pharmagreen Provides Company Update For Its Shareholders

  • globenewswire.com

    Pharmagreen Extends the Letter of Intent Timeline with Advanced Bio-Oil Technologies Ltd.

  • investorplace.com

    10 Penny Stocks That You Can Have for Less Than a Dime